Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- XenoPort, Inc. Q3 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Rachel McMinn with Cowen & Company. Rachel McMinn – Cowen & Company Thanks very much, and thanks, Ron, for talking about the disappointing news first. I think you're probably the first guy I've talked to this year...
- Earnings calls 2008-11-24
Additional Resources
- Astellas and Fujitsu Sign Agreement for Information-System Outsourcing
- Tokyo, Japan, Oct 28, 2005 - JCN Newswire - Astellas Pharma Inc. (TSE: 4503) and Fujitsu Limited (TSE: 6702) today announced that they have reached an information-system outsourcing agreement on October 28. Under the agreement, the operation of Astellas' information systems which has been handled by Astellas Systems Co.,Ltd....
- Research articles 2005-10-28
- Astellas and Pfizer Reached Settlement on Declaratory Judgment Action Relating to Lipitor Agreement
- Tokyo, Japan, Jan 26, 2007 - JCN Newswire - Pfizer Japan Inc. and Astellas Pharma Inc. announced that a settlement has been reached today by Pfizer, Pfizer's affiliate, and Astellas, which are the parties to a Development and Marketing Agreement for a hypercholesterolemia drug "LipitorR" manufactured and distributed by...
- Research articles 2007-01-26
- Astellas Pharma US, Inc. Chooses Cyclone Commerce to Enable Secure, Visible Supply Chain
- Cyclone Commerce, the Collaborative Commerce Company, today announced that Astellas Pharma US, Inc. Astellas, US subsidiary of the global pharmaceutical company Astellas Pharma, Inc., has selected Cyclone's Trade Activity Manager TAM to help support a safe and secure supply chain. This new agreement comes on the heels of Astellas'...
- Research articles 2005-10-11
- Astellas Proposes to Acquire CV Therapeutics for $1Billion
- Eben Tessari submits: Astellas (ALPMF.PK) announced that it has submitted a proposal to the Board of Directors of CV Therapeutics to acquire all outstanding common shares of CV Therapeutics for $16.00 per share in cash. The proposal represents a 41% premium to the closing share price of CV Therapeutics on...
- External links 2009-01-27
- Astellas Announces Offer to Buy CV Therapeutics
- Eben Tessari submits: Astellas (ALPMF.PK) announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all outstanding shares of common stock of CV Therapeutics CVTX at a price of US$16.00 per share. The offer and withdrawal rights are scheduled to expire at 12:01 a.m., New...
- External links 2009-03-02
- Astellas Pharma Sues Toyo Pharmar and Aska Pharmaceutical for Patent
- Tokyo, Nov 30, 2005 - JCN - Astellas Pharma announced on November 29 that it has filed a lawsuit against Toyo Pharmar and Aska Pharmaceutical for infringement on Astellas' patents on tamsulosin hydrochloride in the Tokyo District Court. The suit seeks monetary damages and an injunction of infringing products, namely...
- Research articles 2005-11-30
- Astellas Pharma Submits NDA for FK506 Immunosuppressant to FDA
- Tokyo, Dec 26, 2005 - JCN - Astellas Pharma announced on December 26 that its US subsidiary Astellas Pharma US has filed a New Drug Application for FK506 modified release formulation tacrolimus, its proprietary immunosuppressant, with the US Food and Drug Administration FDA.
- Research articles 2005-12-26
- Will CV Therapeutics Get a Higher Price from Astellas?
- Kirk Shinkle submits: Tokyo-based pharma company Astellas Pharma offered $1 billion in cash or $16 a share for CV Therapeutics CVTX, which makes small molecule cardiovascular drugs including angina treatment Ranexa. The deal is a 41 percent premium to CVTX's closing price, and shares promptly jumped today in expectation of...
- External links 2009-01-27
- Astellas Pharma US, Inc. Selects Dendrite for Sample Compliance Solutions; Dendrite's Robust and Intuitive Compliance Solutions Chosen to Increase Regulatory Compliance and Accountability of Prescription Drug Samples
- BEDMINSTER, N.J. -- Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of pharmaceutical industry solutions, today announced that Astellas Pharma US, Inc., a pharmaceutical company dedicated to improving the health of populations around the world, signed a three-year contract to outsource its sample accountability and compliance processes to Dendrite. ...
- Research articles 2006-08-14
- Astellas' Current Setback Underscores Need for Pipeline Expansion
- EP Vantage submits: The spectre of approval for generic versions of transplant drug Prograf, which has been stalking Astellas (ALPMF.PK) for some months now, has materialised in the realms of reality with news that Novartis’s NVS Sandoz unit is about to launch a copycat version of the product in...
- External links 2009-08-13
- Theravance and Astellas Finalize Collaboration on Telavancin, Investigational Antibiotic for Serious Infections
- Theravance, Inc. (NASDAQ: THRX) announced today that the previously announced collaboration with Astellas Pharma Inc. for the development and commercialization of Theravance's investigational antibiotic, telavancin, was finalized after receiving US regulatory clearance on November 28th. As a result of the finalization of this transaction, Theravance received an upfront payment...
- Research articles 2005-12-05
- Capgemini Announces Broadened IT Outsourcing Agreement to Facilitate Merger Integration for Astellas in the U.S.; U.S. Pharmaceutical Company Anticipates Improvements in Efficiency, Service Levels to Support Growth
- NEW YORK -- Capgemini America, Inc. announced it has expanded its relationship with Astellas US LLC in an agreement that focuses on strategic IT systems and support services that will help enable the pharmaceutical company's efficient growth in the United States.
- Research articles 2006-08-16
- Astellas Pharma's Immunosuppressant Prograf Now Available in Europe
- Tokyo, Apr 24, 2006 - JCN - Astellas Pharma recently announced the European Commission's approval of the Company's proprietary immunosuppressant Prograf tacrolimus for the prophylaxis use of transplant rejection in heart transplant recipients in all EU countries. The announcement results from the European Commission's decision to harmonize the...
- Research articles 2006-04-24
- Toray and Astellas Pharma Announce of the Acquisition of Marketing Approval for the Pulmonary Arterial Hypertension Agent Careload® LA Tablets 60mu/g in Japan
- Tokyo, Japan, Oct 22, 2007 - JCN Newswire - Toray Industries Inc. (TSE: 3402) and Astellas Pharma Inc. (TSE: 4503) today announced that Toray has obtained marketing approval for its oral PGI2 derivative prolonged release, CareloadR LA Tablets 60mu/g (generic name: beraprost sodium), to be indicated for pulmonary arterial hypertension...
- Research articles 2007-10-23
- NeurogesX: Astellas Deal a Major Positive
- Zacks.com submits: By Jason Napodano On June 22, 2009, NeurogesX NGSX Analyst Report announced that it has entered into a development and commercialization partnership for Qutenza, the company’s cutaneous patch for neuropathic pain, with Astellas Pharmaceuticals (ALPMF.PK). NeurogesX has licensed for commercialization Qutenza in all 27 EU...
- External links 2009-06-22
- Ingenuity Systems Broadens Use of Their Products to Japanese Market With License Agreement to Astellas Pharma Inc.
- REDWOOD CITY, California, December 5 /PRNewswire/ -- - Ingenuity's Product Platform Selected for Usability and Content Quality After an Extensive Review of Competing Products Ingenuity Systems announced a global licensing deal to provide Astellas Pharma Inc. with its Ingenuity Pathways Analysis IPA...
- Research articles 2006-12-05
- Cardiome Pharma Corp and Tokyo-based Astellas Pharma Inc must supply additional information on their proposed treatment for irregular heart rhythms, putting off a US decision on approval for three months
- Cardiome Pharma Corp Vancouver BC and Tokyo-based Astellas Pharma Inc must supply additional information on their proposed treatment for irregular heart rhythms, putting off a US decision on approval for three months. The demand from the Food and Drug Administration for more data means the agency won't act...
- Research articles 2007-09-03
- Deals of the Week: Trick or Treat!
- (Top row, L-R: Wyeth, Genentech, Schering-Plough;Middle: Sepracor, CV Therapeutics, NitroMed;Bottom: ImClone, Alpharma, Barr Labs) A memo about costume appropriateness sent home recently by Riverside Drive's principal made the following points: ¶They should not depict gangs or horror characters, or be scary. ¶Masks are allowed only during the parade. ¶Costumes may...
- News items 2009-10-30
- Prograf Now Approved for Prophylaxis Use in Heart Transplantation Across Europe.
- TOKYO and LONDON, April 21 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that the European Commission has approved the immunosuppressant PrografR (generic na TOKYO and LONDON, April 21 /PRNewswire/ -- ...
- Research articles 2006-04-21
- << Previous
- page 1 of 1
- Next >>
Presented by the Premiere Rewards Gold Card from American Express